Form 4: Aprea Therapeutics Director Receives Equity Grant
Statement of Changes in Beneficial Ownership
Director Gabriela Gruia was granted 3,135 restricted stock units and 12,555 stock options by Aprea Therapeutics.
Summary
- Director Gabriela Gruia acquired 3,135 restricted stock units (RSUs) on June 16, 2026.
- The director was also granted 12,555 stock options with an exercise price of $0.7293 per share.
- Both the RSUs and the stock options are scheduled to vest in full on June 16, 2027, contingent upon continued service on the board.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
- Retention of board expertise through standard vesting schedules.
Negatives
- Potential for future shareholder dilution upon the exercise of options and settlement of RSUs.
Risks
- Vesting is subject to the director's continued service on the board.
- Market price volatility may impact the future value of the granted equity.
Future Outlook
The equity grants are subject to standard vesting conditions over a one-year period, aligning the director's tenure with the company's performance through June 2027.
Industry Context
StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to ensure board alignment with long-term corporate strategy and shareholder value.
Comparison to Industry Standards
- The use of time-based vesting for director compensation is consistent with standard corporate governance practices for small-cap biotech firms.
- The grant size is typical for board-level compensation packages in companies of similar market capitalization.
Stakeholder Impact
- Minor dilution impact on existing shareholders upon future vesting and exercise.
Next Steps
- Vesting of restricted stock units on June 16, 2027.
- Vesting of stock options on June 16, 2027.
Key Dates
| Date | Description |
|---|---|
| 06/16/2026 | Date of grant for restricted stock units and stock options. |
| 06/17/2026 | Date of filing for the Form 4. |
| 06/16/2027 | Vesting date for both RSUs and stock options. |
| 06/16/2036 | Expiration date for the stock options. |
Keywords
Aprea Therapeutics, APRE, Form 4, Insider Trading, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.